Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
« First ‹ Prev … 37 38 39 40 41 42 43 44 45 … Next › Last »

Make HHS Anti-Industry Again? Kennedy Blames “System, Not The People,” For “Inefficient, Dysfunctional Or Corrupt” Agencies In First Address To Staff

February 19, 2025

Prevision Policy Clips | Disrupting FDA: Agency Managers Unsure Of Who Is Laid Off Until Notified By Affected Staff

February 19, 2025

Prevision Policy Clips | FDA Layoffs Begin: Device Center Appears More Affected In Round One

February 18, 2025

The Kennedy HHS Era Begins With FDA Staff On Edge: “MAHA” Commission Launches With Anti-Industry Themes – But Better Than Some Alternatives

February 14, 2025

Prevision Policy Clips | HHS Secretary Kennedy Defuses Rumors Of 50% Cuts In Staff, But Leadership Purge

February 14, 2025

White House Supports Shutdown Model For DOGE Cuts; Musk Says Cuts Will Be Made “In Partnership” With Agency Heads; UCSF’s Prasad Rumored To Be Seeking FDA Role

February 13, 2025

FDA RMAT Designations Spiking: Agency Granted 43 Requests In FY 2024 And Nine More In First Quarter Of FY ‘25; RMAT Approvals Now Total 13

February 13, 2025

Prevision Policy Clips | FDA/NIH Rare Disease Still On For February 27-28, With Key FDA Officials On Agenda

February 13, 2025

HTA Harmonization? ICER Teams Up With British NICE and Canada’s Drug Agency To Form Partnership To Assess New Health Economics Methods

February 12, 2025

Prevision Policy Clips | DOGE Layoff Order Unveiled, But No Targets Set For FDA

February 12, 2025

The End Of The User Fee Era? DOGE, Budget Cuts Could Undo Core FDA Regulatory Model

February 11, 2025

AI Regulation At FDA May Drive Drug/Device Regulatory Convergence; Guidance Development Highlighted As Key For Field At FOCR Meeting

February 11, 2025

Prevision Policy Clips | FDA Warns Of Medication Errors With Tranexamic Acid Injections, Opens Investigation

February 11, 2025

Prevision Policy Clips | FDA Issues A Guidance: IRB “Checklist”

February 10, 2025

DOGEing FDA: Layoff Threat Looms, With Prospect Of Significant Disruption; Here Are Two Scenarios For What Massive Cuts Could Look Like In The Long Run

February 7, 2025

Prevision Policy Clips | FDA Facing Mass Layoffs? White House Plans Executive Order To Fire HHS Employees

February 7, 2025

Vertex Non-Opioid Pain Product Receives Favorable Notice In House Illicit Drugs Hearing; Will FDA Retain Bipartisan Support Amid Trump Transition?

February 6, 2025

Medicare Part D Stability Drawing More MedPAC Attention; Decline In Standalone Plans May Be Threat To Fee-For-Service Medicare

February 6, 2025

Prevision Policy Clips | CMS Gets DOGEd: Agency Says Two Officials Are Chaperoning

February 6, 2025

Prevision Policy Clips | RFK Confirmation Vote For HHS Likely The Week Of February 10

February 5, 2025

Vaccine Safety Commission Will Likely Be Early Action By Kennedy HHS; Will Commitments To Cassidy Hold The Line On More Drastic Action?

February 4, 2025

Vertex “Breakthrough” Non-Opioid Pain Treatment Journavx Breaks Through FDA Communication Blackout; Pregnancy Safety Will Be Post-Market Activity

February 4, 2025

CMS Prepares For Oz: Former Finance Staffer Carlton Is “Acting” Administrator And Expected To Be Chief Of Staff; Trump 1.0 Veterans Brooks, Brandt And Sutton Return

February 4, 2025

Kennedy Keeps It Vague: HHS Nominee Moving Forward Without Much Clarity On Drug Pricing Plans Or How “MAHA” Will Translate To Policy

February 4, 2025

Prevision Policy Clips | CMS Prepares For Oz: New Leadership Posted Online Includes Acting Administrator

February 4, 2025
« First ‹ Prev … 37 38 39 40 41 42 43 44 45 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2026 Prevision Policy. All Rights Reserved. Privacy Policy